SN
Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
$17.62 -0.11% (-$0.02)
1M -9.96%
Market Cap $1.56B
P/E Ratio -
Div. Yield -
ROE 372.94%
Piotroski F-Score Weak
3/9Valuation
12 /100
Expensive P/S 6.20x
P/B 103.41x
P/E N/A
Growth
0 /100
Declining Book val. growth 48.29%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 97.47%
Net margin 87.60%
FCF margin 87.64%
Quality
5 /100
Poor ROIC 32.12%
ROE 372.94%
Asset turnover 0.36x
Debt
23 /100
High Debt/Equity 39.03x
Current ratio 6.77x
Int. coverage -1.58x
Stability
54 /100
Moderate Beta 0.37x
EPS volatility 20.28%
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o SNDX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael A. Metzger
Employees
298
Headquarters
New York City
Nadchodzące wydarzenia
02 LIS
Earnings
Upcoming earnings report